 |
Video: What is a Stock Split?
|
 |
Sonoma Pharmaceuticals, Inc. is a global healthcare company, which is engaged in developing and producing stabilized hypochlorous acid (HOCl), products for a range of applications, including wound care, eye care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Co.'s product offerings include Lumacyn Clarifying Mist; Regenacyn Advanced Scar Gel; Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel; Microcyn OTC Advanced Wound & Skin Cleanser; Podiacyn Advanced Everyday Foot Care, MicrocynAH and others. According to our SNOA split history records, Sonoma Pharmaceuticals has had 2 splits. | |
 |

Sonoma Pharmaceuticals (SNOA) has 2 splits in our SNOA split history database. The first split for SNOA took place on June 20, 2019. This was a 1 for 9 reverse split, meaning for each 9 shares of SNOA owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 111.111111111111 share position following the split. SNOA's second split took place on August 30, 2024. This was a 1 for 20 reverse split, meaning for each 20 shares of SNOA owned pre-split, the shareholder now owned 1 share. For example, a 111.111111111111 share position pre-split, became a 5.55555555555556 share position following the split.
When a company such as Sonoma Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the SNOA split history from start to finish, an original position size of 1000 shares would have turned into 5.55555555555556 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Sonoma Pharmaceuticals shares, starting with a $10,000 purchase of SNOA, presented on a split-history-adjusted basis factoring in the complete SNOA split history.

Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
06/16/2015 |
|
End date: |
06/13/2025 |
|
Start price/share: |
$289.80 |
|
End price/share: |
$3.09 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-98.93% |
|
Average Annual Total Return: |
-36.50% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$106.60 |
|
Years: |
10.00 |
|
|
 |
Date |
Ratio |
06/20/2019 | 1 for 9 | 08/30/2024 | 1 for 20 |
|
 |